Opinion: The hurried push by Congress to address drug costs shouldn’t undermine the vast savings from generics and biosimilars
Americans rightfully expect Congress to address the ever-increasing prices of brand-name prescription drugs. But the wholesale policy changes now under rushed consideration in Congress will undermine the only proven solution to this long-standing problem: competition from Food and Drug Administration-approved generic and biosimilar medicines.
Generic and biosimilar medicines generated $2 trillion in savings to the U.S. health care system over the last decade. Yet proposals in the reconciliation package will jeopardize the development of these less-expensive drugs, harming Americans rather than helping them.
